NOVELTY - Determining (M1) allergenic potential of an engineered protein (EP) with an altered T-cell epitope from an unaltered protein of interest (POI) comprising immunizing a transgenic mouse with a POI and another mouse with EP, collecting mouse serum, measuring antigen specific immunoglobulins and comparing the immunogenic response of EP and POI in the mice, is new.    USE - (M1) is useful for determining the allergenic potential of an EP (claimed) useful in forming hyper and hypo-allergenic compositions. Such compositions include cleaning compositions, textile treatments, contact lens cleaning solutions or products, peptide hydrolysis products, waste treatment products, cosmetic formulations for skin, hair and oral care, pharmaceuticals such as blood clot removal products, research products such as enzymes and therapeutics including vaccines. (II) is useful in formulating various detergent compositions, for e.g. in bar or liquid soap applications, dish care formulation, peptide hydrolysis, waste treatment, textile applications, in animal feed such as part of animal feed additive, to treat silk or wool, stone washing, depilling, dehairing, softening and other textile treatments. (IV) is useful for altering the immunogenicity of a POI, including peptides to be used as T-cell vaccines, or peptides or proteins to be used as therapeutic agent against e.g. cancer, infectious diseases and autoimmune diseases, and also lipases, cellulases, proteases, reductases, oxidases, isomerases, kinases, amylases, transferases, and phosphatases. (IV) is useful to identify and modify epitopes in e.g. human factor VIII, to prevent neutralizing responses.    DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:    (1) a variant (II) of POI comprising a T-cell epitope, which differs from POI by having an altered T-cell epitope such that the variant and the polypeptide produce different immunogenic responses in an individual;    (2) determining (III) the immunogenic response produced by a protein, by obtaining from a single blood source a solution of dendritic cells and a solution of naive CD4+ and/or CD8+ T-cells, promoting differentiation in the dendritic cells, combining the solution of differentiated dendritic cells and the naive CD4+ and/or CD8+ T cells with the protein and measuring the proliferation of the T-cells; and    (3) altering (IV) the immunogenicity of POI by determining the immunogenicity of the polypeptide, identifying a T-cell epitope in the polypeptide and altering the T-cell epitope so as to alter the immunogenicity of the polypeptide.